4.66

2.10% -0.10

After Hours: 4.69 0.03 +0.64%

Oramed Pharmaceuticals Inc (ORMP)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Oramed Pharmaceuticals Inc stock is traded at $4.66, with a volume of 144.35K. It is down -2.10% in the last 24 hours and up +9.65% over the past month. Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

Previous Close:

$4.76

Open:

$4.81

24h Volume:

144.35K

Relative Volume:

0.49

Market Cap:

$193.84M

Revenue:

$2.00M

Net Income/Loss:

$109.16M

P/E Ratio:

1.8038

EPS:

2.5835

Net Cash Flow:

$-9.11M

1W Performance:

-6.99%

1M Performance:

+9.65%

6M Performance:

+37.06%

1Y Performance:

+91.77%

1-Day Range:

$4.65

$4.82

1-Week Range:

$4.65

$5.01

52-Week Range:

$2.09

$5.47

Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile

Name

Oramed Pharmaceuticals Inc

Sector

Healthcare (1069)

Industry

Biotechnology (595)

Phone

646-844-1164

Address

1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY

Employee

Twitter

@OramedPharma

Next Earnings Date

2026-08-13

Latest SEC Filings

ORMP's Discussions on Twitter

Compare ORMP vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORMP Oramed Pharmaceuticals Inc	4.66	193.84M	2.00M	109.16M	-9.11M	2.5835
VRTX Vertex Pharmaceuticals Inc	515.44	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	781.49	80.46B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.39	61.58B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	143.97	57.48B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.77	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-23	Downgrade	Canaccord Genuity	Buy → Hold
Feb-18-22	Initiated	Cantor Fitzgerald	Overweight
Apr-20-21	Initiated	Canaccord Genuity	Buy
Feb-09-21	Initiated	National Securities	Buy
Dec-03-20	Initiated	Alliance Global Partners	Buy
Mar-11-20	Initiated	Aegis Capital	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
Dec-11-17	Resumed	B. Riley FBR, Inc.	Buy
May-26-16	Reiterated	FBR Capital	Outperform
Dec-01-15	Reiterated	H.C. Wainwright	Buy
Nov-19-15	Initiated	FBR Capital	Outperform
Apr-13-15	Resumed	MLV & Co	Buy
Jan-30-14	Reiterated	Aegis Capital	Buy
Jan-08-14	Reiterated	Aegis Capital	Buy
Jan-08-14	Initiated	MLV & Co	Buy
Dec-03-13	Initiated	Aegis Capital	Buy

View All

Oramed Pharmaceuticals Inc Stock (ORMP) Latest News

Sep 11, 2026

Oramed shifts focus to investments, sees gains but faces cash and dilution risks - Pluang

Sep 11, 2026

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha

Sep 11, 2026

Sep 10, 2026

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - Kalkine

Sep 10, 2026

Sep 08, 2026

Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal - Stock Titan

Sep 08, 2026

Sep 02, 2026

Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceTPO Profile - vinanet.vn

Sep 02, 2026

Aug 31, 2026

Oramed Pharmaceuticals stock holds at $5 after recent biotech volatility - ad-hoc-news.de

Aug 31, 2026

Aug 28, 2026

Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews

Aug 28, 2026

Aug 19, 2026

Oramed Pharmaceuticals Incorporated Actuals & Estimates (TRADEGATE:OJU1) - TradingView

Aug 19, 2026

Top Penny Stocks To Watch In August 2026 - simplywall.st

Aug 19, 2026

Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayDividend Earnings Report - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Nano Dimension Names Nadav Kidron to Board, Exclusivity with Infinite Epigenetics Ends - Kalkine Media

Aug 18, 2026

Aug 17, 2026

Nano Dimension Appoints Nadav Kidron to Lead Capital Allocation Review - citybiz

Aug 17, 2026

Oramed CEO Joins Nano Dimension Board as Directors Weigh Capital Options - Stock Titan

Aug 17, 2026

Aug 16, 2026

MSN Money - MSN

Aug 16, 2026

Aug 15, 2026

ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC

Aug 15, 2026

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating - MarketBeat

Aug 15, 2026

Aug 14, 2026

Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A - Stock Titan

Aug 14, 2026

ORMP Q4 2025 Earnings: EPS Beat Drives Stock Gain as Revenue Remains N/AReturn On Assets - vinanet.vn

Aug 14, 2026

Aug 10, 2026

Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results - marketbeat.com

Aug 10, 2026

Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Oramed: Q2 Earnings Snapshot - marketscreener.com

Aug 10, 2026

ORAMED PHARMACEUTICALS INC. 2Q 2026: Revenue $0 Net income $78.16M, EPS $1.84— 10-Q Summary - TradingView

Aug 10, 2026

Oramed Pharmaceuticals (NASDAQ: ORMP) pivots to investment model with $116M profit - Stock Titan

Aug 10, 2026

Aug 07, 2026